Prostatype Genomics AB

As of December 31, 2023, Prostatype Genomics AB has 1.91M shares outstanding.

As of December 31, 2023, Prostatype Genomics AB maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2023.

As of the close on October 7, 2026, Prostatype Genomics AB's stock has declined approximately 88.09% over the past 52 weeks.

As of December 31, 2023, Prostatype Genomics AB holds 265,969.58 in cash and equivalents against 1.16M in total debt, resulting in a net debt position of 891,027.84. Total book value stands at 2.45M, with working capital of 141,612.44 providing operational flexibility.

These figures cover the twelve months ended December 31, 2023.

Prostatype Genomics AB's most recent stock split took place on July 6, 2026.